We’re working with multiple partners to accelerate the development of early-stage antiviral platforms and bolster preparedness for potential viral outbreaks. Read more about our new Flexible and Strategic Therapeutics (#FASTx) program collaborators: https://t.co/2P17tTN1AA
Scrip’s Tech Transfer Roundup reports on Tiba Biotech and CEPI planning ahead for the next pandemic. #innovation#mrna#biotech#vaccines#pandemic (https://t.co/ygRljMWxKy)
Pour nos ami(e)s francophones, voici un reportage sur le parteneriat entre CEPI et Tiba Biotech. #innovation#ARNm#vaccins#biotech (https://t.co/46y6V2i5Rn )
Congratulations to one of the @MITSTEX members, @Tibabiotech, for recently becoming a partner with @CEPIvaccines. The new partnership will focus on evaluating Tiba Biotech's next-generation RNA vaccine platform technology. (https://t.co/EwR2UJc4ue)
ICYMI: CEPI and @Tibabiotech are partnering to evaluate Tiba's next-gen RNA vaccine platform tech which could offer substantial advantages over existing RNA vaccines 👇
💉Major boost for vaccines targeting ‘Disease X’.
Cepi has invested in a project to develop cheaper, more effective shots with fewer side effects.
@sneweyy reports for @Telegraph 🔽
https://t.co/6EGhFXNTEA
CEPI announces new partnership with @TibaBiotech to evaluate next-generation #RNA vaccine platform tech to respond to Disease X - the 1st award in our innovation programme to improve rapid-response RNA vaccine tech against future outbreaks 👇
https://t.co/L73cRh2mco
Our CEO, @DrRHatchett said: "We're excited by @Tibabiotech's nanoparticle approach, which we think may reduce adverse reactions and improve the thermostability of mRNA vaccines.” This could make RNA vaccines easier to use and more accessible in many countries
The $2m seed funding will be used to develop an RNA vaccine for Japanese Encephalitis Virus with the aim of generating crucial data about the potential for @TibaBiotech’s platform to make RNA vaccines which are less costly, more effective, and have fewer side effects
Great news re #mRNA animal vaccine development here in NSW in collaboration between Depart. Primary Industries & Tiba Biotech @Tibabiotech in the US! Stay tuned to hear more!
#BREAKINGNEWS: Today #TibaBiotech announced a 5yr, US$MM agreement w/ the Australian state government of New South Wales (#NSW) to develop #mRNA#vaccines against emergency animal diseases that threaten AU’s #livestock industry & domestic #foodsecurity. (https://t.co/UQUbG0HoIH)